Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of US dollars in a Series B+ financing round led by C-Bridge Capital, with contributions from existing investors Cenova Capital and Unicorn Capital Partners. The proceeds will enhance the company’s service capabilities, including operations, technology, and product offerings.
Company Profile
Onekdrug, a B2B pharmaceutical e-commerce platform, focuses on emerging chain and single-store pharmacies. It connects upstream manufacturers with downstream retailers, empowering small-to-medium pharmacies to optimize drug structures, improve operations, and boost profits via its integrated supply chain, operational, and technical service platform.
Business Growth
- Partnerships: Collaborates with nearly 200 manufacturers.
- Revenue: Grew 300% YoY in 2021, with projections to reach RMB 500 million in 2023.
- Market Presence: Operates in 26 Chinese provinces and cities, partnering with over 50,000 pharmacy stores.
Industry Context
Digitalization and capitalization in pharmaceutical B2B have optimized supply chain transactions and improved efficiency, fostering platforms like ysbang.cn, JD Health, Weiming Penguin, and Xiaoyao Pharmaceutical Technology.-Fineline Info & Tech
